Literature DB >> 2169484

Demonstration of progesterone receptors in paraffin wax sections of breast carcinoma.

S Soomro1, S Shousha.   

Abstract

Several immunohistological methods for the demonstration of progesterone receptors were tried on routinely processed paraffin wax sections of breast carcinoma, using Abbott's PgR-ICA monoclonal antibody. The best results were obtained with the avidin-biotin-immunoperoxidase complex method with no prior trypsinisation or DNAse digestion, and with imidazole added to the final diaminobenzidine developing solution. A simple semiquantitative scoring system was used to assess the staining results which were then compared with the results obtained by a standard dextran-coated charcoal biochemical assay. Of 31 cases examined, the results of the two methods were concordant in 25 (81%) of cases. This is near the higher end of the concordance range obtained by several other authors using frozen sections. The discordance encountered in a few cases was possibly the result of sampling errors which are more likely to occur with the chemical rather than the histological method. It is concluded that the method described here is fairly reliable and would greatly simplify the process of assessment of progesterone receptors in breast, and possibly other tumours.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2169484      PMCID: PMC502652          DOI: 10.1136/jcp.43.8.671

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  14 in total

1.  Immunohistological demonstration of progesterone receptor in breast carcinomas: correlation with radioligand binding assays and oestrogen receptor immunohistology.

Authors:  D D Giri; J R Goepel; K Rogers; J C Underwood
Journal:  J Clin Pathol       Date:  1988-04       Impact factor: 3.411

2.  Monoclonal technique to aid decision on endocrine therapy in breast cancer.

Authors:  E Müller-Holzner; A Zeimet; L C Müller; G Daxenbichler; O Dapunt
Journal:  Lancet       Date:  1989-05-20       Impact factor: 79.321

Review 3.  Who needs steroid receptor assays?

Authors:  D M Barnes; I S Fentiman; R R Millis; R D Rubens
Journal:  Lancet       Date:  1989-05-20       Impact factor: 79.321

4.  Who needs steroid receptor assays?

Authors: 
Journal:  Lancet       Date:  1989-07-01       Impact factor: 79.321

5.  Immunocytochemical staining of progesterone receptor in paraffin sections of human breast cancers.

Authors:  M Perrot-Applanat; M T Groyer-Picard; M T Vu Hai; C Pallud; F Spyratos; E Milgrom
Journal:  Am J Pathol       Date:  1989-09       Impact factor: 4.307

6.  Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal antibody. Relation to biochemical assay, disease-free survival, and clinical endocrine response.

Authors:  L P Pertschuk; J G Feldman; K B Eisenberg; A C Carter; W L Thelmo; W P Cruz; S M Thorpe; I J Christensen; B B Rasmussen; C Rose
Journal:  Cancer       Date:  1988-07-15       Impact factor: 6.860

7.  Multiparametric analysis (SAMBA 200) of the progesterone receptor immunocytochemical assay in nonmalignant and malignant breast disorders.

Authors:  C Charpin; J Jacquemier; L Andrac; H Vacheret; M C Habib; B Devictor; M N Lavaut; M Toga
Journal:  Am J Pathol       Date:  1988-08       Impact factor: 4.307

8.  Immunocytochemical detection of estrogen and progesterone receptors in 124 human breast cancers.

Authors:  H J Helin; M J Helle; M L Helin; J J Isola
Journal:  Am J Clin Pathol       Date:  1988-08       Impact factor: 2.493

9.  Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and DNA flow cytometry.

Authors:  H J Helin; M J Helle; O P Kallioniemi; J J Isola
Journal:  Cancer       Date:  1989-05-01       Impact factor: 6.860

10.  Immunocytochemical study with monoclonal antibodies to progesterone receptor in human breast tumors.

Authors:  M Perrot-Applanat; M T Groyer-Picard; F Lorenzo; A Jolivet; M T Vu Hai; C Pallud; F Spyratos; E Milgrom
Journal:  Cancer Res       Date:  1987-05-15       Impact factor: 12.701

View more
  4 in total

1.  U.K. National Breast Screening Programme: first year experience at a histopathology department in an assessment/treating centre.

Authors:  S Shousha
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast.

Authors:  Y A Luqmani; T Campbell; S Soomro; S Shousha; M C Rio; R C Coombes
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

3.  pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response.

Authors:  J A Henry; N H Piggott; U K Mallick; S Nicholson; J R Farndon; B R Westley; F E May
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

4.  Outcome after extended follow-up in a prospective study of operable breast cancer: key factors and a prognostic index.

Authors:  R A Hawkins; A L Tesdale; R J Prescott; T Forster; M A McIntyre; P Baker; W J L Jack; U Chetty; J M Dixon; M E Killen; M J Hulme; W R Miller
Journal:  Br J Cancer       Date:  2002-07-01       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.